腫瘤分子靶向治療的思考-wenkub
2023-06-10 18:14:39 本頁面
【正文】 ancers and is generally associated with advanced disease and poor prognosis,and with resistance to hormone therapy,chemotherapy,or radiotherapy. EGFR Blockade as Cancer Therapy: ’s Hypothesis (Early 1980s) ? The blockade of EGFR activation may inhibit cancr cell proliferation. ? Cancer cells may be selectively sensitive to EGFR inhibition as pared to normal cells. ? Selective antiEGFR agents may be developed. 靶向治療研究已獲得明顯成果 Gleevec Norvatis CML,GIST Gefitinib AstraZenica NSCLC Erlotinib Geech,Roche NSCLC Erbitux ImClone,Merch CRC,H/N Herceptin Geech,Roche Breast Bevacezumab Roche CRC,lung Sorafenib Bayer RCC Sunitinib Pfeizer RCC,GIST 許多新的分子靶向藥物仍在開發(fā)研究中 ZD6474(Vandetanib) AZ lung GW786034(Pazopanib) GSK RCC CA163048(lxabepilone) BMS Breast EGF10453(Lapatinib) GSK Breast Enzastaurin Eillilly GBM,NHL Dasatinib 耐藥 CML PF3512676 Pfeizer lung 靶向治療藥物取得的成功 若干化療無效（失?。┑牟±〉妹黠@療效 Iressa,Tarceva NSCLC Pt based chemo Failure Sorafenib,Sunibinib RCC,Refractory GIST Gleevec CML,GIST Herceptin
外語相關(guān)推薦
鄂ICP備17016276號-1